NTLA News and Press, Intellia Therapeutics Inc. From 06/28/24

2024-06-28 10:28:50 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Searching for quality undiscovered biotech stocks can be a bit like a treasure hunt. The biotech scene is full of intriguing innovators trying to progress their treatments through various c...

2024-06-27 16:48:49 ET Summary The small biotech sector has badly underperformed the major market indices so far in 2024. However, that could change as the Federal Reserve cuts interest rates and/or M&A deal volume picks up across the industry. Today, we highlight three sm...

2024-06-26 07:37:15 ET More on Intellia Therapeutics Intellia Therapeutics Presents Promising In Vivo CRISPR Results Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies Intellia Therapeutics, Inc. (NTLA) Q1 2024 Earnings Call Transcript Intellia...

CAMBRIDGE, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Edward Dulac as Executive Vice President, Chief Financia...

First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapy Follow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28 in the three patients who previously received the lowest dose in the Phase 1 dose...

2024-06-25 14:07:48 ET More on iShares Russell 2000 ETF: IWM: Small Caps Look Unattractive With Deteriorating Earnings Outlook IWM: Favor Small Caps Over The Technology Sector IWM: Not The Economy For Underdogs (Rating Downgrade) Gap between growth and small-...

2024-06-24 16:00:08 ET Dae Gon Ha from Stifel Nicolaus issued a price target of $80.00 for NTLA on 2024-06-24 12:15:00. The adjusted price target was set to $80.00. At the time of the announcement, NTLA was trading at $25.22. The overall price target consensus is at $126...

2024-06-24 11:37:31 ET Summary HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and...

2024-06-24 08:49:49 ET More on Alnylam Pharmaceuticals Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentatio...

2024-06-24 01:43:14 ET Summary Astria Therapeutics stock has fallen 40% since early 2023, but promising early data for its candidate STAR-0215 in treating HAE is helping drive analyst Buy ratings. ATXS stock has a compound called STAR-0310 in development for an immune disorder, wi...